journal
MENU ▼
Read by QxMD icon Read
search

Lancet Respiratory Medicine

journal
https://www.readbyqxmd.com/read/27916480/long-term-efficacy-and-safety-of-%C3%AE-1-proteinase-inhibitor-treatment-for-emphysema-caused-by-severe-%C3%AE-1-antitrypsin-deficiency-an-open-label-extension-trial-rapid-ole
#1
Noel G McElvaney, Jonathan Burdon, Mark Holmes, Allan Glanville, Peter A B Wark, Philip J Thompson, Paul Hernandez, Jan Chlumsky, Helmut Teschler, Joachim H Ficker, Niels Seersholm, Alan Altraja, Riitta Mäkitaro, Joanna Chorostowska-Wynimko, Marek Sanak, Paul I Stoicescu, Eeva Piitulainen, Oliver Vit, Marion Wencker, Michael A Tortorici, Michael Fries, Jonathan M Edelman, Kenneth R Chapman
BACKGROUND: Purified α1 proteinase inhibitor (A1PI) slowed emphysema progression in patients with severe α1 antitrypsin deficiency in a randomised controlled trial (RAPID-RCT), which was followed by an open-label extension trial (RAPID-OLE). The aim was to investigate the prolonged treatment effect of A1PI on the progression of emphysema as assessed by the loss of lung density in relation to RAPID-RCT. METHODS: Patients who had received either A1PI treatment (Zemaira or Respreeza; early-start group) or placebo (delayed-start group) in the RAPID-RCT trial were included in this 2-year open-label extension trial (RAPID-OLE)...
December 1, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27916479/compelling-evidence-for-the-efficacy-of-%C3%AE-1-antitrypsin-augmentation-treatment-for-%C3%AE-1-antitrypsin-deficiency
#2
Ronald G Crystal
No abstract text is available yet for this article.
December 1, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27889441/corrections
#3
(no author information available yet)
No abstract text is available yet for this article.
November 23, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27876247/effect-of-pirfenidone-on-mortality-pooled-analyses-and-meta-analyses-of-clinical-trials-in-idiopathic-pulmonary-fibrosis
#4
Steven D Nathan, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Ian Glaspole, Marilyn K Glassberg, David R Kardatzke, Monica Daigl, Klaus-Uwe Kirchgaessler, Lisa H Lancaster, David J Lederer, Carlos A Pereira, Jeffrey J Swigris, Dominique Valeyre, Paul W Noble
BACKGROUND: In clinical trials of idiopathic pulmonary fibrosis, rates of all-cause mortality are low. Thus prospective mortality trials are logistically very challenging, justifying the use of pooled analyses or meta-analyses. We did pooled analyses and meta-analyses of clinical trials of pirfenidone versus placebo to determine the effect of pirfenidone on mortality outcomes over 120 weeks. METHODS: We did a pooled analysis of the combined patient populations of the three global randomised phase 3 trials of pirfenidone versus placebo-Clinical Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis: Research of Efficacy and Safety Outcomes (CAPACITY 004 and 006; trial durations 72-120 weeks) and Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCEND 016; 52 weeks)-for all-cause mortality, treatment-emergent all-cause mortality, idiopathic-pulmonary-fibrosis-related mortality, and treatment-emergent idiopathic-pulmonary-fibrosis-related mortality at weeks 52, 72, and 120...
November 19, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27876248/pirfenidone-and-mortality-in-idiopathic-pulmonary-fibrosis
#5
Paolo Spagnolo
No abstract text is available yet for this article.
November 18, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27876246/corrections
#6
(no author information available yet)
No abstract text is available yet for this article.
November 18, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27866861/outcomes-after-transplantation-of-lungs-preserved-for-more-than-12-h-a-retrospective-study
#7
Jonathan C Yeung, Thorsten Krueger, Kazuhiro Yasufuku, Marc de Perrot, Andrew F Pierre, Thomas K Waddell, Lianne G Singer, Shaf Keshavjee, Marcelo Cypel
BACKGROUND: Ex-vivo lung perfusion (EVLP) can be used to extend overall lung preservation time by splitting one long cold ischaemic time into two shorter ones and interposing an additional EVLP time. We assessed the outcomes after clinical transplantation of lungs with more than 12 h of preservation time. METHODS: For this retrospective study, we searched the Toronto Lung Transplant Program database for patients who had received at least one lung transplant between Jan 1, 2006, and April 30, 2015, at a single hospital in Toronto, Canada...
November 17, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27865647/uk-government-chokes-on-air-pollution-crisis
#8
Paul Kiet Tang
No abstract text is available yet for this article.
November 16, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27865646/long-term-oxygen-in-copd
#9
Talha Khan Burki
No abstract text is available yet for this article.
November 16, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27864036/comorbidities-and-the-risk-of-mortality-in-patients-with-bronchiectasis-an-international-multicentre-cohort-study
#10
Melissa J McDonnell, Stefano Aliberti, Pieter C Goeminne, Marcos I Restrepo, Simon Finch, Alberto Pesci, Lieven J Dupont, Thomas C Fardon, Robert Wilson, Michael R Loebinger, Dusan Skrbic, Dusanka Obradovic, Anthony De Soyza, Chris Ward, John G Laffey, Robert M Rutherford, James D Chalmers
BACKGROUND: Patients with bronchiectasis often have concurrent comorbidities, but the nature, prevalence, and impact of these comorbidities on disease severity and outcome are poorly understood. We aimed to investigate comorbidities in patients with bronchiectasis and establish their prognostic value on disease severity and mortality rate. METHODS: An international multicentre cohort analysis of outpatients with bronchiectasis from four European centres followed up for 5 years was done for score derivation...
November 15, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27864035/47th-union-world-conference-on-lung-health
#11
Rebecca Akkermans
No abstract text is available yet for this article.
November 15, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27864034/2016-chest-annual-meeting
#12
Rebecca Akkermans
No abstract text is available yet for this article.
November 15, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27864033/bronchiectasis-shaking-off-its-orphan-status
#13
Paul J Torzillo
No abstract text is available yet for this article.
November 15, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27843130/reduction-of-childhood-pneumonia-mortality-in-the-sustainable-development-era
#14
Eric D McCollum, Carina King, Laura L Hammitt, Amy S Ginsburg, Tim Colbourn, Abdullah H Baqui, Katherine L O'Brien
No abstract text is available yet for this article.
November 11, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27825616/vandetanib-in-patients-with-previously-treated-ret-rearranged-advanced-non-small-cell-lung-cancer-luret-an-open-label-multicentre-phase-2-trial
#15
Kiyotaka Yoh, Takashi Seto, Miyako Satouchi, Makoto Nishio, Noboru Yamamoto, Haruyasu Murakami, Naoyuki Nogami, Shingo Matsumoto, Takashi Kohno, Koji Tsuta, Katsuya Tsuchihara, Genichiro Ishii, Shogo Nomura, Akihiro Sato, Atsushi Ohtsu, Yuichiro Ohe, Koichi Goto
BACKGROUND: RET rearrangements are rare oncogenic alterations in non-small-cell lung cancer (NSCLC). Vandetanib is a multitargeted tyrosine kinase inhibitor exhibiting RET kinase activity. We aimed to assess the efficacy and safety of vandetanib in patients with advanced RET-rearranged NSCLC. METHODS: In this open-label, multicentre, phase 2 trial (LURET), patients with advanced RET-rearranged NSCLC continuously received 300 mg of oral vandetanib daily. RET-positive patients were screened using a nationwide genomic screening network of about 200 participating institutions...
November 4, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27825615/targeted-therapy-outcomes-in-ret-rearranged-lung-cancers-drug-or-driver
#16
Alexander Drilon
No abstract text is available yet for this article.
November 4, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27814987/nice-approves-osimertinib-for-advanced-lung-cancer
#17
Talha Khan Burki
No abstract text is available yet for this article.
November 1, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27773668/study-does-not-support-early-intubation-in-paediatric-in-hospital-cardiac-arrest
#18
Tony Kirby
No abstract text is available yet for this article.
October 20, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27773667/pulmonary-effects-of-timing-of-antiretroviral-therapy-initiation
#19
Halima Dawood
No abstract text is available yet for this article.
October 20, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27773666/added-value-of-combined-endobronchial-and-oesophageal-endosonography-for-mediastinal-nodal-staging-in-lung-cancer-a-systematic-review-and-meta-analysis
#20
Daniël A Korevaar, Laurence M Crombag, Jérémie F Cohen, René Spijker, Patrick M Bossuyt, Jouke T Annema
BACKGROUND: Guidelines recommend endosonography with fine-needle aspiration for mediastinal nodal staging in non-small-cell lung cancer, but most do not specify whether this should be through endobronchial endoscopy (EBUS), oesophageal endoscopy (EUS), or both. We assessed the added value and diagnostic accuracy of the combined use of EBUS and EUS. METHODS: For this systematic review and random effects meta-analysis, we searched MEDLINE, Embase, BIOSIS Previews, and Web of Science, without language restrictions, for studies published between Jan 1, 2000, and Feb 25, 2016...
October 20, 2016: Lancet Respiratory Medicine
journal
journal
47869
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"